Article Text

Download PDFPDF

4.4 Pharmacoepidemiology
O4-4.5 Associations of angiotensin-II receptor blockers and ACE inhibitors with Alzheimer's disease: a nested case-control study within the UK general practice research database
  1. N Davies1,
  2. P Kehoe1,2,
  3. Y Ben-Shlomo1,
  4. R Martin1
  1. 1University of Bristol, Bristol, UK
  2. 2Frenchay Hospital, Bristol, UK


Objectives To investigate whether angiotensin II receptor blockers (ARBs) and ACE inhibitors (ACE-Is) are more strongly associated with Alzheimer's disease (AD) than other anti-hypertensive drugs.

Methods Nested case-control analysis within the UK general practice research database (n≈10 million), with prospectively recorded anti-hypertensive prescribing data. Cases aged ≥60 years and diagnosed between 1997 and 2008 (5797 with AD, 2186 with vascular dementia, 1214 with unspecified / other dementia) were matched to up to four controls by age, general practice and gender. We computed ORs and dose response effects for AD, vascular and unspecified / other dementia, comparing those prescribed ARBs or ACE-Is for at least 6 months with patients prescribed other anti-hypertensives. We controlled for matching factors, co-morbidities, smoking status, an area measure of socioeconomic status, consultation rate and blood pressure and accounted for reverse causality by introducing time-lags of up to 8 years prior to diagnosis / index date.

Results Patients diagnosed with AD, vascular and unspecified / other dementia had fewer prescriptions for ARBs and ACE-Is. Inverse associations with AD were strongest for ARBs (OR 0.47, 95% CI 0.37 to 0.58) compared with ACE-Is (OR 0.76, 95% CI 0.69 to 0.84) (p difference <0.001). Associations of ARBs with AD were stronger than for vascular dementia (p difference=0.01) and unspecified / other dementia (p difference=0.23). There were inverse dose-response relationships between ARBs and ACE-Is with AD (both p trend <0.01). The inverse association of ACE-Is with AD diminished when using longer time lags but the ARB-AD association persisted.

Conclusions Patients with AD were around half as likely to be prescribed ARBs. Further randomised controlled trial evidence is required to rigorously test these findings.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.